Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lymphoma Gene Therapy
Reports summarize lymphoma gene therapy research from Baylor College of Medicine
July 8th, 2008
Researchers detail in 'Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor,' new data in lymphoma. According to a study from the United States, "Transforming growth factor (TGF)-beta is produced in most human tumors and markedly inhibits tumor antigen-specific cellular immunity, representing a major obstacle to the success of tumor immunotherapy. TGF-beta is produced in Epstein-Barr virus (EBV)-positive Hodgkin disease and non-Hodgkin lymphoma both by the tumor cells and by infiltrating T-regulatory cells and may contribute the escape of these tumors from infused EBV-specific T cells." "To determine whether tumor...
Source: Cancer Weekly (2008-07-08)
|
